Compare BXMT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | BHVN |
|---|---|---|
| Founded | 1966 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1998 | 2022 |
| Metric | BXMT | BHVN |
|---|---|---|
| Price | $12.41 | $13.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $21.38 | ★ $29.08 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | ★ 154.70 | 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.31 | $7.48 |
| 52 Week High | $20.67 | $18.57 |
| Indicator | BXMT | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 24.34 | 45.06 |
| Support Level | N/A | $8.75 |
| Resistance Level | $14.27 | $14.52 |
| Average True Range (ATR) | 0.34 | 0.95 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 9.28 | 33.99 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.